[{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Leo Pharma | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute"},{"orgOrder":0,"company":"Galician Research Group on Digestive Tumors","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"Galician Research Group on Digestive Tumors","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galician Research Group on Digestive Tumors \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Galician Research Group on Digestive Tumors \/ Leo Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Dalteparin sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Galician Research Group on Digestive Tumors

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Galician Research Group on Digestive Tumors

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 23, 2022

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 12, 2021

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Leo Pharma | Sunnybrook Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Innohep

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 20, 2015

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Centre Hospitalier Universitaire de Saint Etienne

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Centre Hospitalier Universitaire de Saint Etienne

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2014

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Christine Ribic

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Christine Ribic

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : McMaster University | Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 18, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Fragmin

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 18, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Study Phase : Phase IV

                          Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 11, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of Aarhus

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          University of Aarhus

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 08, 2011

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Aarhus University Hospital | Leo Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Innohep

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2010

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank